Carriers, channels and chloroquine efficacy in Guinea-Bissau

Trends in Parasitology

Volumn 24, Issue 2, 2008, Pages 49-51

  Ursing, Johan ^a,b   Rombo, Lars ^a,c   Kofoed, Poul Erik ^b,d   Gil, José P ^a,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Project de Saúde de Bandim   (Guinea-Bissau)

^c Mälarsjukhuset ^*  (Sweden)

^d KOLDING HOSPITAL   (Denmark)

^e UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DRUG CARRIER; ION CHANNEL;

CHANNEL GATING; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG TOLERABILITY; DRUG TRANSPORT; GUINEA-BISSAU; HUMAN; MALARIA; NONHUMAN; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG RESISTANCE; GUINEA-BISSAU; HUMANS; ION CHANNELS; MALARIA, FALCIPARUM; MEMBRANE TRANSPORT PROTEINS; MUTATION; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; TREATMENT OUTCOME;

EID: 38549179855     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2007.11.002     Document Type: Short Survey

References (25)

1. Djimde A., et al. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344 (2001) 257-263
2. Zhang H., et al. The antimalarial drug resistance protein Plasmodium falciparum chloroquine resistance transporter binds chloroquine. Biochemistry 43 (2004) 8290-8296
3. Sanchez C.P., et al. Is PfCRT a channel or a carrier? Two competing models explaining chloroquine resistance in Plasmodium falciparum. Trends Parasitol. 23 (2007) 332-339
4. Sanchez C.P., et al. Evidence for a pfcrt-associated chloroquine efflux system in the human malarial parasite Plasmodium falciparum. Biochemistry 44 (2005) 9862-9870
5. Sanchez C.P., et al. Evidence for a substrate specific and inhibitable drug efflux system in chloroquine resistant Plasmodium falciparum strains. Biochemistry 43 (2004) 16365-16373
6. Sanchez C.P., et al. Differences in trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum. Mol. Microbiol. 64 (2007) 407-420
7. Sanchez C.P., et al. Trans stimulation provides evidence for a drug efflux carrier as the mechanism of chloroquine resistance in Plasmodium falciparum. Biochemistry 42 (2003) 9383-9394
8. Egan T.J., et al. Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochem. J. 365 (2002) 343-347
9. Sugioka Y., et al. A ferriprotoporphyrin IX-chloroquine complex promotes membrane phospholipid peroxidation. A possible mechanism for antimalarial action. FEBS Lett. 223 (1987) 251-254
10. Bray P.G., et al. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol. Microbiol. 56 (2005) 323-333
11. Homewood C.A., et al. Lysosomes, pH and the anti-malarial action of chloroquine. Nature 235 (1972) 50-52
12. Bray P.G., et al. Access to hematin: the basis of chloroquine resistance. Mol. Pharmacol. 54 (1998) 170-179
13. Bray P.G., et al. PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol. Microbiol. 62 (2006) 238-251
14. Hayward R., et al. The pH of the digestive vacuole of Plasmodium falciparum is not associated with chloroquine resistance. J. Cell Sci. 119 (2006) 1016-1025
15. Kuhn Y., et al. Quantitative pH measurements in Plasmodium falciparum-infected erythrocytes using pHluorin. Cell. Microbiol. 9 (2007) 1004-1013
16. Warhurst D.C., et al. Lysosomes and drug resistance in malaria. Lancet 360 (2002) 1527-1529
17. Hellgren U., et al. Chloroquine resistant Plasmodium falciparum malaria in Guinea-Bissau. Trans. R. Soc. Trop. Med. Hyg. 85 (1991) 36
18. Kofoed P.E., et al. Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations. Trans. R. Soc. Trop. Med. Hyg. 101 (2007) 231-238
19. Ursing J., et al. Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau. Am. J. Trop. Med. Hyg. 76 (2007) 844-848
20. Ursing J., et al. Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage?. Infect. Genet. Evol. 7 (2007) 555-561
21. Dunyo S., et al. Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS. Clin. Trials 1 (2006) e14
22. Thomas S.M., et al. In vitro chloroquine susceptibility and PCR analysis of pfcrt and pfmdr1 polymorphisms in Plasmodium falciparum isolates from Senegal. Am. J. Trop. Med. Hyg. 66 (2002) 474-480
23. Smith E.R., and Klein-Schwartz W. Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J. Emerg. Med. 28 (2005) 437-443
24. Laufer M.K., et al. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 355 (2006) 1959-1966
25. Ginsburg H. Should chloroquine be laid to rest?. Acta Trop. 96 (2005) 16-23